MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-18-2026
Charles River Laboratories International Operating Cycle 2011-2026 | CRL
Annual Operating Cycle Charles River Laboratories International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 65 | 67.7 | 67.7 | 64 | 65 | 70.6 | 107 | 109 | 121 | 113 | 113 | 112 | 112 | 110 | 105 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 121 | 64 | 93.4 |
Quarterly Operating Cycle Charles River Laboratories International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68.2 | 67.4 | 68.5 | - | 116 | - | - | - | 111 | 106 | 68.3 | - | 35.5 | 32.7 | 66.9 | - | 66.4 | 62.6 | 68 | 71.3 | 75.8 | 82.6 | 73 | 67.9 | 70.2 | 71.3 | 74.4 | 71.6 | 73.6 | 73.6 | 83.3 | 82 | 84.5 | 83.6 | 81.3 | 71.2 | 78 | 76.5 | 81.5 | 69.6 | 70.5 | 72.6 | 75.2 | 71.4 | 71.9 | 69 | 72.9 | 69.6 | 68.9 | 68.7 | 66.4 | - | 66.5 | 65.1 | 61.9 | - | 60.8 | 58.5 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 116 | 32.7 | 72.5 |
Operating Cycle of other stocks in the Diagnostics research industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
161 | $ 110.31 | -2.79 % | $ 33.5 B |  USA |
 |
Centogene N.V.
CNTG
|
170 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Waters Corporation
WAT
|
834 | $ 289.46 | -3.69 % | $ 17.2 B | USA |
 |
Enzo Biochem
ENZ
|
206 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
91.7 | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Sotera Health Company
SHC
|
80.3 | $ 13.12 | -3.14 % | $ 3.73 B | USA |
 |
Heska Corporation
HSKA
|
177 | - | - | $ 1.31 B | USA |
 |
BioNano Genomics
BNGO
|
315 | $ 1.15 | -0.43 % | $ 6.26 M | USA |
 |
DermTech
DMTK
|
114 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
73.8 | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
202 | $ 62.39 | -5.61 % | $ 24.3 B | USA |
 |
Accelerate Diagnostics
AXDX
|
489 | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
202 | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
11.8 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
185 | - | 0.12 % | $ 80.1 M | China |
 |
HTG Molecular Diagnostics
HTGM
|
216 | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
97.9 | $ 23.59 | -4.49 % | $ 655 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.22 K | - | - | $ 10.7 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
54.2 | $ 195.05 | -1.56 % | $ 21.7 B | USA |
 |
Organovo Holdings
ONVO
|
79.8 | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M | USA |
 |
Biocept
BIOC
|
134 | - | -13.05 % | $ 7.29 M | USA |
 |
PerkinElmer
PKI
|
92.2 | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
368 | - | - | $ 21.2 M | USA |
 |
Interpace Biosciences
IDXG
|
79.2 | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K |  Israel |
 |
QIAGEN N.V.
QGEN
|
172 | - | - | $ 10.6 B |  Niderland |
 |
Neogen Corporation
NEOG
|
213 | $ 8.71 | -4.86 % | $ 1.89 B | USA |
 |
Chembio Diagnostics
CEMI
|
164 | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
71.8 | $ 264.08 | -1.6 % | $ 22 B | USA |
 |
Psychemedics Corporation
PMD
|
61.3 | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
49.8 | $ 25.69 | -5.55 % | $ 33.3 M | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 16.68 | -4.55 % | $ 889 M | USA |
 |
Quotient Limited
QTNT
|
432 | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Syneos Health
SYNH
|
102 | - | - | $ 4.46 B | USA |
 |
Renalytix AI plc
RNLX
|
15.9 | - | 5.66 % | $ 22.7 M |  Britain |
 |
VolitionRx Limited
VNRX
|
52.3 | $ 0.19 | -0.08 % | $ 18.3 M |  Singapore |
|
Biodesix
BDSX
|
41.7 | $ 14.29 | -2.16 % | $ 1.85 B | USA |
 |
Biomerica
BMRA
|
204 | $ 1.99 | -5.52 % | $ 4.57 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
275 | $ 16.61 | -10.22 % | $ 179 M | China |
 |
Bioventus
BVS
|
259 | $ 8.93 | -3.62 % | $ 595 M | USA |
 |
Co-Diagnostics
CODX
|
405 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Meridian Bioscience
VIVO
|
238 | - | - | $ 1.49 B | USA |